Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) — – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and […]